267 related articles for article (PubMed ID: 23917087)
1. Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.
Kaur M; Singh M; Silakari O
Eur J Med Chem; 2013 Sep; 67():434-46. PubMed ID: 23917087
[TBL] [Abstract][Full Text] [Related]
2. Spleen tyrosine kinases: biology, therapeutic targets and drugs.
Riccaboni M; Bianchi I; Petrillo P
Drug Discov Today; 2010 Jul; 15(13-14):517-30. PubMed ID: 20553955
[TBL] [Abstract][Full Text] [Related]
3. Syk kinase as a treatment target for therapy in autoimmune diseases.
Kyttaris VC; Tsokos GC
Clin Immunol; 2007 Sep; 124(3):235-7. PubMed ID: 17662659
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic prospect of Syk inhibitors.
Ruzza P; Biondi B; Calderan A
Expert Opin Ther Pat; 2009 Oct; 19(10):1361-76. PubMed ID: 19670961
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
Liao C; Hsu J; Kim Y; Hu DQ; Xu D; Zhang J; Pashine A; Menke J; Whittard T; Romero N; Truitt T; Slade M; Lukacs C; Hermann J; Zhou M; Lucas M; Narula S; DeMartino J; Tan SL
Arthritis Res Ther; 2013 Oct; 15(5):R146. PubMed ID: 24286216
[TBL] [Abstract][Full Text] [Related]
6. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
[TBL] [Abstract][Full Text] [Related]
7. Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors.
Choi JS; Hwang HJ; Kim SW; Lee BI; Lee J; Song HJ; Koh JS; Kim JH; Lee PH
Bioorg Med Chem Lett; 2015 Oct; 25(20):4441-6. PubMed ID: 26384287
[TBL] [Abstract][Full Text] [Related]
8. [Involvement of Syk in pathology of systemic autoimmune disease].
Iwata S; Yamaoka K; Niiro H; Nakano K; Wang SP; Saito K; Akashi K; Tanaka Y
Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(1):56-61. PubMed ID: 22374444
[TBL] [Abstract][Full Text] [Related]
9. Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases.
Pamuk ON; Tsokos GC
Arthritis Res Ther; 2010; 12(6):222. PubMed ID: 21211067
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.
Robak T; Robak E
Expert Opin Investig Drugs; 2012 Jul; 21(7):921-47. PubMed ID: 22612424
[TBL] [Abstract][Full Text] [Related]
11. Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013.
Norman P
Expert Opin Ther Pat; 2014 May; 24(5):573-95. PubMed ID: 24555683
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors.
Hirabayashi A; Mukaiyama H; Kobayashi H; Shiohara H; Nakayama S; Ozawa M; Tsuji E; Miyazawa K; Misawa K; Ohnota H; Isaji M
Bioorg Med Chem; 2008 Oct; 16(20):9247-60. PubMed ID: 18823784
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of WO2011134971, chiral 1,6-napthyridine Syk kinase inhibitors.
Norman P
Expert Opin Ther Pat; 2012 Mar; 22(3):335-9. PubMed ID: 22356552
[TBL] [Abstract][Full Text] [Related]
14. Comment on "Therapeutic targeting of Syk in autoimmune diabetes".
Kapoor S
J Immunol; 2011 Feb; 186(4):1885; author reply 1886-5. PubMed ID: 21289311
[No Abstract] [Full Text] [Related]
15. Discovery and development of spleen tyrosine kinase (SYK) inhibitors.
Singh R; Masuda ES; Payan DG
J Med Chem; 2012 Apr; 55(8):3614-43. PubMed ID: 22257213
[No Abstract] [Full Text] [Related]
16. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.
Braselmann S; Taylor V; Zhao H; Wang S; Sylvain C; Baluom M; Qu K; Herlaar E; Lau A; Young C; Wong BR; Lovell S; Sun T; Park G; Argade A; Jurcevic S; Pine P; Singh R; Grossbard EB; Payan DG; Masuda ES
J Pharmacol Exp Ther; 2006 Dec; 319(3):998-1008. PubMed ID: 16946104
[TBL] [Abstract][Full Text] [Related]
17. Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK).
Farmer LJ; Bemis G; Britt SD; Cochran J; Connors M; Harrington EM; Hoock T; Markland W; Nanthakumar S; Taslimi P; Ter Haar E; Wang J; Zhaveri D; Salituro FG
Bioorg Med Chem Lett; 2008 Dec; 18(23):6231-5. PubMed ID: 18938080
[TBL] [Abstract][Full Text] [Related]
18. Selective spleen tyrosine kinase inhibition delays autoimmune arthritis in mice.
Zhang Z; Cao C; Sun S; Xu Q
Mol Med Rep; 2015 Aug; 12(2):2902-6. PubMed ID: 25955571
[TBL] [Abstract][Full Text] [Related]
19. Getting Syk: spleen tyrosine kinase as a therapeutic target.
Geahlen RL
Trends Pharmacol Sci; 2014 Aug; 35(8):414-22. PubMed ID: 24975478
[TBL] [Abstract][Full Text] [Related]
20. New spleen tyrosine kinase inhibitors: patent applications published during 2011-2013.
Thorarensen A; Kaila N
Pharm Pat Anal; 2014 Sep; 3(5):523-41. PubMed ID: 25374321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
